Xeris Biopharma Holdings, Inc. XERS · NASDAQ
$10.31 +2.38% (+$0.24)
Summary
49 / 100 · Bulios Score
What speaks for it
- Revenue grew by 38% a year over the last 3 years.
- Analysts expect revenue to grow by 33% this fiscal year.
- Out of every 100 USD of revenue, 17 USD is left as free cash.
- It earns 13 USD a year on every 100 USD of invested capital.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 70% a year over 5 years. Over the last 3 years it grew by 38% a year. For the next fiscal year analysts expect revenue to grow by 33%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $17.2M.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 10
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $14 is 36% above today's price. 91% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 85%
- Keveyis 14%
- Product, Other 0.6%
By region
The company reports no revenue by region.
Product brings in 85% of revenue.
Segments in detail